Neurocrine Biosciences announced that Eiry W. Roberts, M.D., will rejoin the company's executive management team as Chief Medical Officer, effective immediately, while Sanjay Keswani, M.D., departs the company by mutual agreement. Dr. Roberts previously served as Neurocrine's Chief Medical Officer from 2018 to 2025 and has continued as a Strategic Advisor since then. In that role she led indication-expansion efforts for INGREZZA and the crinecerfont development program that led to U.S. Food and Drug Administration approval of CRENESSITY. Before joining Neurocrine in 2018, she spent 26 years at Eli Lilly and Company, including as Vice President, Research and Development, and she currently serves on the Board of Directors of Bausch Health Companies. Chief Executive Officer Kyle W. Gano said Dr. Roberts' deep knowledge of the company, its pipeline and clinical development programs provides strong continuity as Neurocrine advances multiple late-stage programs and prepares for several important clinical milestones.
Neurocrine Biosciences IncNeurocrine reappoints Eiry W. Roberts as Chief Medical Officer, providing continuity as it advances late-stage programs.
Eli Lilly and Company
Bausch Health Companies Inc